Concepedia

Tim Eisen

TE

Statistics

Publications

3

Citations

123

H-Index

3

Active since

2005

Affiliations

Bayer (United States)(Current)

Tim Eisen is an author at Bayer (United States) specializing in medicine, oncology, and kidney cancer.

Publications per year

2005–2009

3

Publications

3

Final findings from a phase II, placebo-controlled, randomized discontinuation trial (RDT) of sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (RCC)

Mark J. Ratain, Tim Eisen, Walter M. Stadler et al. · Journal of Clinical Oncology · 2005 · 97 citations

Medicine, Oncology, Pharmacology +16

MAGE-A3 Antigen-Specific Cancer Immunotherapeutic (ASCI) as adjuvant therapy in resected stage IB/II non-small cell lung cancer (NSCLC): from proof-of-concept to phase III trial (MAGRIT)

Tim Eisen, J. Vansteenkiste, M. Zieliński et al. · Lung Cancer · 2009 · 16 citations

Medicine, Immunology, Oncology +16

964 CLINICAL BENEFIT OF SORAFENIB IN THE ELDERLY WITH ADVANCED RENAL CELL CARCINOMA: SUBGROUP ANALYSIS OF THE APPROACHES IN RENAL CANCER GLOBAL EVALUATION TRIAL (TARGETS)

Tim Eisen, Stéphane Oudard, Cezary Szczylik et al. · European Urology Supplements · 2007 · 10 citations

Medicine, Oncology, Pharmacotherapy +10

1–3 of 3